On the other hand, GLP-1 receptor agonists reduced AD pathologic markers and improved memory in the absence of diabetes experimentally19; recently, a randomized double-blind placebo-controlled trial reported that long-term treatment with dulaglutide, a long-acting GLP-1 receptor agonist, reduced the hazard of substantive cognitive impairment in type 2 diabetic patients20. Here, GLP1R is linked to Alzheimer disease.